These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22855394)

  • 41. Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine.
    Chen GL; Lau YF; Lamirande EW; McCall AW; Subbarao K
    Proc Natl Acad Sci U S A; 2011 Jan; 108(3):1140-5. PubMed ID: 21199945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.
    Beyer WE; Nauta JJ; Palache AM; Giezeman KM; Osterhaus AD
    Vaccine; 2011 Aug; 29(34):5785-92. PubMed ID: 21624411
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.
    Song JY; Cheong HJ; Seo YB; Kim IS; Noh JY; Heo JY; Choi WS; Lee J; Kim WJ
    Clin Vaccine Immunol; 2012 May; 19(5):638-41. PubMed ID: 22379067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study.
    McVernon J; Laurie K; Barr I; Kelso A; Skeljo M; Nolan T
    Influenza Other Respir Viruses; 2011 Jan; 5(1):7-11. PubMed ID: 21138535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L; Vinnemeier CD; Meyer S; Witte K; Marx L; Theeß W; Burchard GD; Rolling T; Cramer JP
    Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients.
    Manuel O; Humar A; Berutto C; Ely L; Giulieri S; Lien D; Meylan PR; Weinkauf J; Pascual M; Nador R; Aubert JD; Kumar D
    J Heart Lung Transplant; 2011 Jun; 30(6):679-84. PubMed ID: 21377898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Key points in evaluating immunogenicity of pandemic influenza vaccines: A lesson from immunogenicity studies of influenza A(H1N1)pdm09 vaccine.
    Ohfuji S; Kobayashi M; Ide Y; Egawa Y; Saito T; Kondo K; Ito K; Kase T; Maeda A; Fukushima W; Hirota Y
    Vaccine; 2017 Sep; 35(39):5303-5308. PubMed ID: 28784284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multivariate analysis of factors affecting the immunogenicity of trivalent inactivated influenza vaccine in school-age children.
    Freeman G; Ng S; Perera RA; Fang VJ; Ip DK; Leung GM; Peiris JS; Cowling BJ
    Epidemiol Infect; 2015 Feb; 143(3):540-9. PubMed ID: 24786933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.
    Oh CE; Lee J; Kang JH; Hong YJ; Kim YK; Cheong HJ; Ahn YJ; Kim SH; Lee HJ
    Vaccine; 2010 Aug; 28(36):5857-63. PubMed ID: 20600483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
    Clark TW; Pareek M; Hoschler K; Dillon H; Nicholson KG; Groth N; Stephenson I
    N Engl J Med; 2009 Dec; 361(25):2424-35. PubMed ID: 19745215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Seropositivity of influenza A H1NI in mothers and infants following maternal vaccination with trivalent seasonal influenza vaccine after the 2009 pandemic.
    Chao AS; Chang YL; Chao A; Wu TS; Yang LY; Lian R; Huang YC
    Taiwan J Obstet Gynecol; 2017 Feb; 56(1):37-40. PubMed ID: 28254223
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial.
    Scheifele DW; Ward BJ; Dionne M; Vanderkooi OG; Loeb M; Coleman BL; Li Y;
    Vaccine; 2012 Jul; 30(32):4728-32. PubMed ID: 22652402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination.
    Choi YS; Baek YH; Kang W; Nam SJ; Lee J; You S; Chang DY; Youn JC; Choi YK; Shin EC
    Clin Vaccine Immunol; 2011 Sep; 18(9):1519-23. PubMed ID: 21813667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan.
    Mondini G; Braga PE; Lopes MH; Sartori AMC; Miyaji KT; Infante V; Randi BA; Timenetsky MDCST; Ferreira JCOA; Sakita NK; Precioso AR
    Rev Inst Med Trop Sao Paulo; 2018 Jul; 60():e37. PubMed ID: 30066805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
    Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
    Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
    Morçӧl T; Hurst BL; Tarbet EB
    Vaccine; 2017 Aug; 35(35 Pt B):4569-4577. PubMed ID: 28716554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.
    Houser KV; Yamshchikov GV; Bellamy AR; May J; Enama ME; Sarwar U; Larkin B; Bailer RT; Koup R; Paskel M; Subbarao K; Anderson E; Bernstein DI; Creech B; Keyserling H; Spearman P; Wright PF; Graham BS; Ledgerwood JE;
    PLoS One; 2018; 13(11):e0206837. PubMed ID: 30388160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Responses after one dose of a monovalent influenza A (H1N1) 2009 inactivated vaccine in Chinese population--a practical observation.
    Sun F; Zhang Y; Tian D; Zheng M; Liu L; Zhang R; Dai Z; Chen J; Li T; Lu H
    Vaccine; 2011 Sep; 29(38):6527-31. PubMed ID: 21767595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.